Is genetic testing required for lpilimumab?

Ipilimumab does not generally require genetic testing to determine indications for its use. Its use is based primarily on a patient's tumor type and clinical history rather than specific genetic test results. This drug is generally approved to treat certain types of cancer, such as malignant melanoma (skin cancer) and metastatic colorectal cancer.

However, in some cases, genetic testing may be helpful in determining the appropriateness of ipilimumab treatment and predicting efficacy. For example, in the treatment of malignant melanoma, some experimental studies are exploring immune-related genetic markers to help determine which patients are more likely to benefit from ipilimumab treatment. However, these genetic tests have not yet become standard diagnostic or treatment options.

As a result, the use of ipilimumab is still primarily based on tumor type and patient clinical status, but as the field of immunotherapy continues to be researched and developed, genetic testing may play a more important role in future treatment decisions. Patients should always have a detailed consultation with their medical professional to understand the treatment options that are best for them.

Ipilimumab is not currently available in China, so patients cannot purchase it domestically and can only purchase it through overseas purchase channels. There are only original drugs of Ipilimumab abroad, mainly Turkish original drugs and Bristol-Myers Squibb original drugs. The price of Turkish original drugs is around 12,000 yuan, and the specification is 50mg/10ml; Bristol-Myers Squibb's original drug costs about 11,700 yuan, and its specifications are also 50mg/10ml. The ingredients of the two drugs are the same.